AstraZeneca’s Nexium Marketing Targeted In Consumer Suit
This article was originally published in The Tan Sheet
Executive Summary
A lawsuit filed in U.S. Superior Court in Los Angeles alleges AstraZeneca employed "unfair and deceptive" practices in promoting its proton pump inhibitor Nexium (esomeprazole)
You may also be interested in...
AstraZeneca subpoenaed
Pennsylvania U.S. Attorney is seeking documents related to the formulary status of proton pump inhibitors Prilosec and Nexium at a regional health maintenance organization and a national pharmacy benefits manager, AstraZeneca announces in recent third-quarter earnings report. The firm says it "intends to cooperate fully" with the document requests. AstraZeneca's Nexium marketing is the target of a consumer suit filed in U.S. Superior Court last month (1"The Tan Sheet" Oct. 24, 2004, p. 11)...
Claritin
Consumer coalition lawsuit against Schering-Plough claims non-sedating antihistamine DTC ads misleadingly imply higher degree of efficacy than has been proven. Prescription Access Litigation Project seeks refunds for consumers' costs of potential switch drug. Schering's legal battles also extend to GMP problems; on Aug. 9, Public Citizen renewed request for criminal investigation into firm's recall of 59 mil. Rx albuterol inhalers
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC